1. Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange
- Author
-
Stephanie N. DuBose, Shivani Agarwal, Linda A. DiMeglio, Anne L. Peters, Nicole C. Foster, Carol J. Levy, Sarah K. Lyons, Gabriel I. Uwaifo, Jennifer L. Sherr, and Sarit Polsky
- Subjects
Blood Glucose ,Pediatrics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Biomedical Engineering ,Bioengineering ,Glycemic Control ,Insulin Infusion Systems ,Pregnancy ,Internal Medicine ,Medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Glycemic ,Glycated Hemoglobin ,Type 1 diabetes ,business.industry ,Blood Glucose Self-Monitoring ,Original Articles ,Device use ,medicine.disease ,Diabetes Mellitus, Type 1 ,Female ,Pregnant Women ,business - Abstract
Objectives: To examine changes in device use and glycemic outcomes for pregnant women from the T1D Exchange Clinic Registry between the years 2010-2013 and 2016-2018. Methods: Participant-reported device use and glycemic outcomes were compared for women aged 16-40 years who were pregnant at the time of survey completion, comparing 2010-2013 (cohort 1) and 2016-2018 (cohort 2). Hemoglobin A1c results within 30 days prior to survey completion were obtained from medical records. Results: There were 208 pregnant women out of 5,236 eligible participants completing the questionnaire in cohort 1 and 47 pregnant women out of 2,818 eligible participants completing the questionaire in cohort 2. Continuous glucose monitor (CGM) use while pregnant trended upward among cohort 2 (70% vs 37%, P = .02), while reported continuous subcutaneous insulin infusion (CSII) use while pregnant declined (76% vs 64%, P = .04). HbA1c levels trended downward (6.8% cohort 1 vs 6.5% cohort 2, P = .07). Conclusions: Self-reported CGM use while pregnant increased over the studied intervals whereas CSII use decreased. Additional evaluation of device use and the potential benefits for T1D pregnancies is needed.
- Published
- 2020